InMed Pharmaceuticals (INM) Gross Margin (2022 - 2025)
Historic Gross Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 35.99%.
- InMed Pharmaceuticals' Gross Margin fell 30200.0% to 35.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.69%, marking a year-over-year increase of 19700.0%. This contributed to the annual value of 34.53% for FY2025, which is 105800.0% up from last year.
- InMed Pharmaceuticals' Gross Margin amounted to 35.99% in Q3 2025, which was down 30200.0% from 44.2% recorded in Q2 2025.
- Over the past 5 years, InMed Pharmaceuticals' Gross Margin peaked at 67.95% during Q2 2023, and registered a low of 153.07% during Q3 2022.
- Its 5-year average for Gross Margin is 23.44%, with a median of 36.16% in 2024.
- Examining YoY changes over the last 5 years, InMed Pharmaceuticals' Gross Margin showed a top increase of 1554200bps in 2023 and a maximum decrease of -402600bps in 2023.
- Over the past 5 years, InMed Pharmaceuticals' Gross Margin (Quarter) stood at 42.08% in 2021, then crashed by -34bps to 27.92% in 2022, then decreased by -6bps to 26.14% in 2023, then surged by 59bps to 41.46% in 2024, then decreased by -13bps to 35.99% in 2025.
- Its Gross Margin was 35.99% in Q3 2025, compared to 44.2% in Q2 2025 and 13.92% in Q1 2025.